Study: J&J's ustekinumab effective against psoriasis

10/3/2007 | MarketWatch · Wall Street Journal (free content), The

Patients taking the Johnson & Johnson psoriasis drug experienced a significant reduction in the skin condition after 12 weeks, researchers report. The study involving about 1,230 patients found that more than two-thirds of patients who received the drug reported at least a 75% reduction in the severity of the skin disease within three months. J&J, which plans to file for regulatory approval of the drug this year, is also testing the compound as a possible treatment for Crohn's disease.

View Full Article in:

MarketWatch · Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN